Fig. 1
From: Prioritization of therapeutic targets for cancers using integrative multi-omics analysis
Study design and flow diagrams. The transcriptomic, proteomic, druggable genetic and metabolomic association with cancers were recognized through comprehensive methods. 18 gene transcripts (TWAS-significant, SMR-significant and PP.H4 > 0.8), 1 protein-coding genes (PWAS-significant, MR-significant and PP.H4 > 0.8) and 5 druggable genes (SMR-significant and PP.H4 > 0.8) were included in phenotype scanning and enrichment analysis. Additionally, we conducted two-samples MR analyzes to identify 2 metabolic pathways significantly associated with cancers. TWAS transcriptome-wide association studies, PWAS proteome-wide association studies, MR Mendelian randomization, SMR summary-data-based Mendelian randomization, PP.H4 posterior probability that two traits are associated with a single causal variant, eQTL expression quantitative trait loci, GTEx v8 genotype-tissue expression project version 8, EA European American